Cochlear-backed Epiminder has its sights set on an Australian initial public offering after securing Food and Drug Administration approval for its flagship Minder device.
The medtech, which has spent eight years developing its sub-scalp device to detect seizures for epilepsy patients, will announce on Tuesday that it’s received clearance to market its device in the US.
Loading…